bezafibrate (Bezalip)

^[1]^[2]

Indications

* not shown to reduce cardiovascular events^[1] (avoid)

* gemfibrozil is agent of choice in this class

↑ ^1.0 ^1.1 Therapeutics Letter #108. Therapeutics Initiative Drugs to Avoid. http://www.ti.ubc.ca/2018/01/04/108-drugs-avoid/
↑ ^2.0 ^2.1 Corpechot C, Chazouilleres O, Rousseau A et al A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. N Engl J Med 2018; 378:2171-2181. June 7, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29874528 https://www.nejm.org/doi/full/10.1056/NEJMoa1714519
Carey EJ Progress in Primary Biliary Cholangitis. N Engl J Med 2018; 378:2234-2235. June 7, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29874531 https://www.nejm.org/doi/full/10.1056/NEJMe1804945